Peter Heald

9.9k total citations · 2 hit papers
92 papers, 5.7k citations indexed

About

Peter Heald is a scholar working on Dermatology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Peter Heald has authored 92 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Dermatology, 44 papers in Pathology and Forensic Medicine and 33 papers in Epidemiology. Recurrent topics in Peter Heald's work include Cutaneous lymphoproliferative disorders research (67 papers), Lymphoma Diagnosis and Treatment (33 papers) and Nail Diseases and Treatments (20 papers). Peter Heald is often cited by papers focused on Cutaneous lymphoproliferative disorders research (67 papers), Lymphoma Diagnosis and Treatment (33 papers) and Nail Diseases and Treatments (20 papers). Peter Heald collaborates with scholars based in United States, Austria and Italy. Peter Heald's co-authors include Richard L. Edelson, Lynn D. Wilson, Madeleine Duvic, L. Laroche, Eric C. Vonderheid, Michael Girardi, Maritza Pérez, Carole L. Berger, Elise A. Olsen and Gary S. Wood and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Peter Heald

90 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

2007 926 citations Elise A. Olsen, Eric C. Vonderheid et al. profile →
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy

1987 918 citations Richard L. Edelson, Carole L. Berger et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Heald United States	32	4.1k	2.6k	2.1k	2.1k	900	92	5.7k
Eric C. Vonderheid United States	44	5.5k 1.3×	3.6k 1.4×	3.1k 1.4×	2.4k 1.2×	1.6k 1.7×	154	7.5k
Nicola Pimpinelli Italy	37	3.8k 0.9×	2.5k 0.9×	1.6k 0.7×	2.1k 1.0×	1.4k 1.6×	204	6.0k
Florent Grange France	35	2.0k 0.5×	1.4k 0.5×	534 0.2×	1.8k 0.9×	1.9k 2.1×	145	4.1k
Mauro Alaibac Italy	24	1.1k 0.3×	690 0.3×	527 0.2×	872 0.4×	994 1.1×	191	3.0k
R. Cerio United Kingdom	32	1.1k 0.3×	554 0.2×	489 0.2×	1.1k 0.6×	1.0k 1.1×	146	3.4k
Paul Schwarzenberger United States	34	486 0.1×	672 0.3×	4.1k 1.9×	1.1k 0.5×	1.7k 1.9×	112	7.2k
Koji Izutsu Japan	35	418 0.1×	2.0k 0.8×	1.0k 0.5×	511 0.2×	2.0k 2.3×	265	4.6k
G Stingl Austria	20	1.1k 0.3×	656 0.3×	2.0k 0.9×	286 0.1×	255 0.3×	32	3.2k
Charlotte M. Proby United Kingdom	50	2.5k 0.6×	355 0.1×	843 0.4×	4.2k 2.0×	2.8k 3.1×	159	6.8k
Maritza Pérez United States	20	1.2k 0.3×	412 0.2×	632 0.3×	367 0.2×	300 0.3×	48	2.2k

Countries citing papers authored by Peter Heald

Since Specialization

Citations

This map shows the geographic impact of Peter Heald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Heald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Heald more than expected).

Fields of papers citing papers by Peter Heald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Heald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Heald. The network helps show where Peter Heald may publish in the future.

Co-authorship network of co-authors of Peter Heald

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Heald. A scholar is included among the top collaborators of Peter Heald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Heald. Peter Heald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Sa Rang, Alexandra Charos, William Damsky, et al.. (2018). Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports. 4(5). 443–445. 49 indexed citations

Poligone, Brian, Lynn D. Wilson, Antonio Subtil, & Peter Heald. (2009). Primary Cutaneous T-Cell Lymphoma Localized to the Lower Leg. Archives of Dermatology. 145(6). 677–82. 7 indexed citations

Heald, Peter, et al.. (2007). Persistent agmination of lymphomatoid papulosis: An equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 57(6). 1005–1011. 21 indexed citations

Heald, Peter, et al.. (2003). Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Journal of the American Academy of Dermatology. 49(5). 801–815. 94 indexed citations

Duvic, Madeleine, Timothy M. Kuzel, Elise A. Olsen, et al.. (2002). Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®). Clinical Lymphoma. 2(4). 222–228. 85 indexed citations

Duvic, Madeleine, Kenneth B. Hymes, Peter Heald, et al.. (2001). Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results. Journal of Clinical Oncology. 19(9). 2456–2471. 479 indexed citations

Argiris, Athanassios, Peter Heald, Timothy M. Kuzel, et al.. (2001). Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma. Investigational New Drugs. 19(4). 321–326. 9 indexed citations

Girardi, Michael & Peter Heald. (2000). CUTANEOUS T-CELL LYMPHOMA AND CUTANEOUS GRAFT-VERSUS-HOST DISEASE. Dermatologic Clinics. 18(3). 417–423. 4 indexed citations

Sinha, Animesh A. & Peter Heald. (1998). ADVANCES IN THE MANAGEMENT OF CUTANEOUS T-CELL LYMPHOMA. Dermatologic Clinics. 16(2). 301–311. 14 indexed citations

10.

Quirós, Peter A., Barry M. Kacinski, Irwin M. Braverman, et al.. (1997). Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal of Radiation Oncology*Biology*Physics. 38(5). 1027–1035. 78 indexed citations

11.

Herrick, C & Peter Heald. (1997). THE DYNAMIC INTERPLAY OF MALIGNANT AND BENIGN T CELLS IN CUTANEOUS T-CELL LYMPHOMA. Dermatologic Clinics. 15(1). 149–157. 5 indexed citations

12.

Wilson, Lynn D., Peter A. Quirós, Peter Heald, et al.. (1996). Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 35(1). 69–73. 55 indexed citations

13.

Layton, Marcelle, Maritza Pérez, Peter Heald, & Jan E. Patterson. (1993). An Outbreak of Mupirocin-Resistant Staphylococcus aureus on a Dermatology Ward Associated with an Environmental Reservoir. Infection Control and Hospital Epidemiology. 14(7). 369–375. 114 indexed citations

14.

Heald, Peter, Alain H. Rook, Bruce U. Wintroub, et al.. (1992). Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. Journal of the American Academy of Dermatology. 27(3). 427–433. 175 indexed citations

15.

Heald, Peter & Richard L. Edelson. (1991). Immunology of Cutaneous T-Cell Lymphoma. JNCI Journal of the National Cancer Institute. 83(6). 400–404. 15 indexed citations

16.

DODD, W. ALAN, Bernard S. Goffe, R. W. Goltz, et al.. (1990). A trial of the Actiderm dermatological patch and topical corticosteroids in the treatment of psoriasis vulgaris. Cutis. 46(1). 84–88. 6 indexed citations

17.

Heald, Peter, Maritza Pérez, Inger Christensen, et al.. (1990). Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.. PubMed. 62(6). 629–38. 72 indexed citations

18.

Kacinski, Barry M., Jean‐Marc Schwartz, G McKiernan, et al.. (1989). Sustained complete remission of skin disease in advanced CTCL. International Journal of Radiation Oncology*Biology*Physics. 17. 226–226. 1 indexed citations

19.

Edelson, Richard L., Carole L. Berger, Francis P. Gasparro, et al.. (1987). Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy. New England Journal of Medicine. 316(6). 297–303. 918 indexed citations breakdown →

20.

Itakura, Mitsuo, Richard L. Sabina, Peter Heald, & E W Holmes. (1981). Basis for the control of purine biosynthesis by purine ribonucleotides.. Journal of Clinical Investigation. 67(4). 994–1002. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact